Cite
Teclistamab Population Pharmacokinetics and Exposure-Response Relationship Support 1.5 Mg/Kg Dose Regimen in Relapsed/Refractory Multiple Myeloma
MLA
Miao, Xin, et al. “Teclistamab Population Pharmacokinetics and Exposure-Response Relationship Support 1.5 Mg/Kg Dose Regimen in Relapsed/Refractory Multiple Myeloma.” Blood, vol. 140, no. 1, Number 1 Supplement 1, Nov. 2022, pp. 4382–83. EBSCOhost, https://doi.org/10.1182/blood-2022-162859.
APA
Miao, X., Wu, L. S., Wang Lin, S. X., Xu, Y., Chen, Y., Iwaki, Y., Kobos, R., Stephenson, T., Kemmerer, K., Uhlar, C. M., Banerjee, A., Goldberg, J. D., Trancucci, D., Verona, R., Pei, L., Su, Y., Ouellet, D., Garfall, A. L., Krishnan, A. Y., … Zhou, H. (2022). Teclistamab Population Pharmacokinetics and Exposure-Response Relationship Support 1.5 Mg/Kg Dose Regimen in Relapsed/Refractory Multiple Myeloma. Blood, 140(1, Number 1 Supplement 1), 4382–4383. https://doi.org/10.1182/blood-2022-162859
Chicago
Miao, Xin, Liviawati S. Wu, Shun Xin Wang Lin, Yan Xu, Yang Chen, Yuki Iwaki, Rachel Kobos, et al. 2022. “Teclistamab Population Pharmacokinetics and Exposure-Response Relationship Support 1.5 Mg/Kg Dose Regimen in Relapsed/Refractory Multiple Myeloma.” Blood 140 (1, Number 1 Supplement 1): 4382–83. doi:10.1182/blood-2022-162859.